training module 6 – version 1.1 for internal use only ® liver cancer treatment
TRANSCRIPT
Training Module 6 – Version 1.1
For Internal Use Only
®
Surgical Resection
Liver Transplantation
Radiation Therapy
Radiofrequenzy Ablation
Cryosurgery
Local Chemotherapy
Percutaneous Ethanol Injection
Systemic Chemotherapy
Liver Cancer Treatment
Training Module 6 – Version 1.1
For Internal Use Only
®
Surgical Resection
Liver Transplantation
Radiation Therapy
Radiofrequenzy Ablation
Cryosurgery
Local Chemotherapy
Percutaneous Ethanol Injection
Systemic Chemotherapy
Liver Cancer Treatment
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Surgical resection may be a curative treatment for HCC
Surgical Resection
…only 10% - 30% of patients with HCC are eligible for surgical resection because their pre-existing liver disease limits the regenerative capacity of their liver
But…
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Surgical Resection
In secondary liver cancer the 5 year survival after resection is between 20 and 40% , compared to 0% without resection.
In HCC survival rates can be up to 75% after 5 years.
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
In resected cancer patients with metastatic disease recurrence has occurred in 50% to 75% of the patients and remains the most important problem.
Surgical Resection
Absolute contraindications to resection of metastatic liver cancer are
Presence of extra hepatic metastasis
Inability to remove all hepatic disease
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Anatomic Liver Resections
I
II
III
IV
portal veinVI
V
VIII
VII
IX
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Remaining liver function
Number of tumour nodules (usually 3 or less)
Proximity or involvement of major hepatic vascular structures
Number of lobes affected (usually 1 only)
Tumour size (remaining liver function)
In summary the limiting factors for a surgical resection of primary and secondary liver tumours are:
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Intraoperative complications are:
Postoperative complications are:
Liver failure
Ascites
Pleural effusions
Intraperitoneal infection
Major bile leak
Gastrointestinal bleeding
Blood loss
Surgical Resection - Complications
Training Module 6 – Version 1.1
For Internal Use Only
®
Surgical Resection
Liver Transplantation
Radiation Therapy
Radiofrequenzy Ablation
Cryosurgery
Local Chemotherapy
Percutaneous Ethanol Injection
Systemic Chemotherapy
Liver Cancer Treatment
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Transplantation for hepatic malignancies is indicated in the setting of either unresectable lesion(s), or coexistent cirrhosis resulting in both inadequate hepatic reserve and prohibitive portal hypertension
Liver Transplantation
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Limitations:
R.L. Jenkis et al., Cancer Chemother Pharmacol 1989: 23: 104-109
Not all patients are eligible for transplantation
Availability of donor organs
Patients require lifelong immunosupression
Contraindicated in patients with secondary liver cancer
Liver Transplantation
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Survival data for patients with HCC undergoing liver transplantation:
R.L. Jenkis et al., Cancer Chemother Pharmacol 1989: 23: 104-109
49% at one year
37% at two years
30% at three years
Liver Transplantation
Training Module 6 – Version 1.1
For Internal Use Only
®
Surgical Resection
Liver Transplantation
Radiation Therapy
Radiofrequenzy Ablation
Cryosurgery
Local Chemotherapy
Percutaneous Ethanol Injection
Systemic Chemotherapy
Liver Cancer Treatment
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Radiation Therapy
The use of radiotherapy is limited as the liver does not tolerate large doses (above 35Gy).
Nevertheless radiotherapy has a useful role in palliation of pain, nausea and vomiting.
Training Module 6 – Version 1.1
For Internal Use Only
®
Surgical Resection
Liver Transplantation
Radiation Therapy
Radiofrequenzy Ablation
Cryosurgery
Local Chemotherapy
Percutaneous Ethanol Injection
Systemic Chemotherapy
Liver Cancer Treatment
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Radiofrequency Ablation
The radiofrequency ablation uses heat to destroy an entire tumour with minimal damage to adjacent vital structures.
Radiofrequency is used as a source of thermal energy
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Radiofrequency Ablation - Procedure
Thin needles are placed under imaging guidance into the tumour
Multiple electrode array
3 parallel electrodes
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Radiofrequency Ablation - Procedure
The needles are connected to a radiofrequency generator and function as an electrode
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Radiofrequency Ablation - Procedure
During the procedure a temperature of 500C to 1000C is maintained throughout the entire target volume
The field of coagulation should include a 0.5 to 1cm margin of normal tissue
Coagulation necrosis
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Radiofrequency Ablation
Limitations:
Not practicable for multiple lesions
Tumours in vascular environments
Only small tumours suitable (<3-4cm)
Relatively new technique
Limited number of studies published
Training Module 6 – Version 1.1
For Internal Use Only
®
Surgical Resection
Liver Transplantation
Radiation Therapy
Radiofrequenzy Ablation
Cryosurgery
Local Chemotherapy
Percutaneous Ethanol Injection
Systemic Chemotherapy
Liver Cancer Treatment
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Cryosurgery
The cryosurgery uses subzero temperatures to destroy an entire tumour with minimal damage to adjacent vital structures.
The terms cryosurgery, cryoablation and cryotherapy are interchangeable
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Cryosurgery versus conventional surgery
Cryosurgery can treat
or
bilobar disease
as many as 8 or 10 lesions
tumours adjacent to major vessels
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Cryosurgery
In cryosurgery tumour cells are exposed to temperatures below -20°C for at least one minute
This is generally lethal to living cells because:
Ice crystals damage cell plasma membrane
Ice crystals create a grinding effect
Small arterioles and venules are destroyed
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Cryosurgery
The operative exposure is similar to liver resection
Cryoprobes are placed within the tumour centers
The probes are flushed with cryogen
Tip temperatures of -100°C are achieved
The freeze front is monitored by ultrasound
Aim is to freeze the whole tumour plus 1cm margin
Procedure:
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Cryosurgery
With this technique, patients with primary and secondary liver cancer can be treated if
the tumour size is less than 6cm
less than 50% cumulative liver volume is affected
Limitations:
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Cryosurgery
Outcome:
HCC with a tumour size less than 5cm
1 year survival 92.2%3 year survival 75.5%5 year survival 47.8%
Colorectal metastasis (mean diameter 4.4cm)
1 year survival 82.4%3 year survival 32.3%5 year survival 13.4%
Training Module 6 – Version 1.1
For Internal Use Only
®
Surgical Resection
Liver Transplantation
Radiation Therapy
Radiofrequenzy Ablation
Cryosurgery
Local Chemotherapy
Percutaneous Ethanol Injection
Systemic Chemotherapy
Liver Cancer Treatment
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Local Chemotherapy
There are two different approaches to local chemotherapy treatment:
Transcatheter Arterial Chemoembolization (TACE)
Hepatic Artery Infusional Chemotherapy (HAC or HAI)
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Local Chemotherapy
There are two different approaches to local chemotherapy treatment:
Transcatheter Arterial Chemoembolization (TACE)
Hepatic Artery Infusional Chemotherapy (HAC or HAI)
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Transcatheter Arterial Chemoembolization (TACE)
TACE aims to deliver high doses of a chemotherapeutic drug directly to the tumour and to simultaneously enhance the effect by embolization of the tumour vascularization
The chemotherapeutic drug plus the embolic agent are injected via a hepatic artery catheter
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Transcatheter Arterial Chemoembolization (TACE)
The major component is Lipiodol, which is iodized poppy seed oil
Common chemotherapeutic agents are Doxorubicin, Cisplatin and Mitomycin C
Other embolic agents like polyvinyl alcohol (PVA), gel foam, coils and degradable microspheres are also used
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Transcatheter Arterial Chemoembolization (TACE)
Proposed effect of Lipiodol:
Enhanced accumulation in and around tumours
May enter tumour cells and induce death
Occlusive to tumour vascularity
Less than 0.2ml/kg of Lipiodol are regarded as a safe dose. If of the whole liver needs to be embolized, 10-20ml are used. The normal dose is around 1ml per cm tumour diameter
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Transcatheter Arterial Chemoembolization (TACE)
Advantages versus systemic chemotherapy:
Delivery of higher doses to the tumour
Less systemic side effects
Embolization cuts tumour off essential nutrients
Embolization enhances dwell time of drug
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Transcatheter Arterial Chemoembolization (TACE)
Indications:
Unresectable HCCUnresectable metastasisReduction of progressionDownsize tumour before resection
Major Contraindications:
Extrahepatic diseasePoor liver functionLarge arteriovenous shuntingHepatic encephalopathy
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Transcatheter Arterial Chemoembolization (TACE)
Patient workup:
Imaging (CT, MRT)
Labs
Angiography
Procedure:
Installation of the highly viscous TACE mixture via a hepatic artery catheter. Almost always a repeated treatment is necessary.
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Transcatheter Arterial Chemoembolization (TACE)
Complications:
Post embolization syndromeAcute progressive hepatic insuffiency (APHI)Pulmonary oil embolismLiver abscessCholecystitisNon-target embolization of the gutGastrointestinal bleedingOthers
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Transcatheter Arterial Chemoembolization (TACE)
Outcome:
HCC
1 year survival 54-88%2 year survival 33-64%3 year survival 18-51%5 year survival <6%
Colorectal metastasis
1 year survival 78%2 year survival 35%3 year survival 15%
In general the outcome is hard to quantify in a meta-analysis as many different protocols are used by different groups
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Local Chemotherapy
There are two different approaches to local chemotherapy treatment:
Transcatheter Arterial Chemoembolization (TACE)
Hepatic Artery Infusional Chemotherapy (HAC or HAI)
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Hepatic Artery Infusional Chemotherapy (HAC/HAI)
Like TACE, HAI (HAC) aims to deliver high doses of a chemotherapeutic drug directly to the tumour
To achieve this, a drug is used which is highly extracted by the liver during the first pass with a short systemic half life time
This is drug is usually Floxuridine(FUDR)
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Hepatic Artery Infusional Chemotherapy (HAC/HAI)
The chemotherapeutic drug is automatically delivered by an implanted pump which pumps it directly into the hepatic artery
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Hepatic Artery Infusional Chemotherapy (HAC/HAI)
Complications:
Surgical complications (pump placement)Acute gastric or duodenal ulcersCatheter or hepatic artery thrombosis (10%)Septic complicationsBiliary sclerosis (20%)
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Hepatic Artery Infusional Chemotherapy (HAC/HAI)
Outcome:
There are no good survival data available. Nevertheless this technique is regarded as efficient with response rates around 50% (42-62).
One source mentions a 2 year survival rate of 47%
Training Module 6 – Version 1.1
For Internal Use Only
®
Surgical Resection
Liver Transplantation
Radiation Therapy
Radiofrequenzy Ablation
Cryosurgery
Local Chemotherapy
Percutaneous Ethanol Injection
Systemic Chemotherapy
Liver Cancer Treatment
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Percutaneous Ethanol Injection (PEI)
PEI is a local tumour ablative technique depending on the toxic effects of ethanol (alcohol)
Ethanol causes
Protein denaturationCellular dehydration
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Percutaneous Ethanol Injection (PEI)
Most common is the ‘Multi-Session’ approach in an outpatient setting
Procedure:
In each session 8-10ml ethanol are injected in the tumour under local anesthesia and ultrasound guidance.
Complications are systemic alcohol intoxication, transient pain and fever
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Percutaneous Ethanol Injection (PEI)
There are only data for HCC available, these only retrieved from retrospective reviews without control.
Outcome:
HCC
1 year survival 93%2 year survival 80%3 year survival 68%
Training Module 6 – Version 1.1
For Internal Use Only
®
Surgical Resection
Liver Transplantation
Radiation Therapy
Radiofrequenzy Ablation
Cryosurgery
Local Chemotherapy
Percutaneous Ethanol Injection
Systemic Chemotherapy
Liver Cancer Treatment
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Systemic Chemotherapy
Systemic chemotherapy is not regarded as an effective treatment, neither in HCC nor in metastatic liver cancer
Liver cancers have been found to be relatively resistant to chemotherapeutic drugs at systemic doses and the reported response rate is less than 30%
The chemotherapy regimen in secondary liver cancer is therefore determined by the type of the primary cancer and only palliative with regard to the liver.
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Management of unresectable metastatic colorectal cancer (mCRC) - principles:
Palliation and control of symptoms
Control of tumour growth
Lengthen progression-free and overall survival
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Chemotherapeutic drugs in the management of unresectable metastatic colorectal cancer (mCRC):
Fluorouracil (5-FU)Uracil analogue, Patented in 1957Still core of most chemotherapy regimens
LeucovorinBiomodulation of 5-FUPotentates the cytotoxic activity of 5-FU
Irinotecan First new drug (mCRC) after more than 30 yearsPlant alkaloid, Topoisomerase I inhibitor
OxaliplatinForms DNA strand cross linksFirst platin analogue effective in CRC
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Chemotherapy regimen in the management of unresectable metastatic colorectal cancer (mCRC):
48 hours (2 days)48 hours (2 days)
Irinotecan 180mg/mIrinotecan 180mg/m22
Leucovorin 200mg/mLeucovorin 200mg/m22
5-FU infusion 600mg/m5-FU infusion 600mg/m2 2 22h22h2h2h 5-FU infusion 600mg/m5-FU infusion 600mg/m2 2 22h22h2h2h
5-FU bolus 400mg/m5-FU bolus 400mg/m22
Leucovorin 200mg/mLeucovorin 200mg/m22
5-FU bolus 400mg/m5-FU bolus 400mg/m22
cycle repeated every 14 dayscycle repeated every 14 days
FOLFIRI (Folinic acid, 5-FU, Irinotecan)
Training Module 6 – Version 1.1
For Internal Use Only
®
Oxaliplatin 85mg/mOxaliplatin 85mg/m22
Leucovorin 200mg/mLeucovorin 200mg/m22
Liver Cancer Treatment
Chemotherapy regimen in the management of unresectable metastatic colorectal cancer (mCRC):
48 hours (2 days)48 hours (2 days)
5-FU bolus 400mg/m5-FU bolus 400mg/m22
5-FU infusion 600mg/m5-FU infusion 600mg/m2 2 22h22h2h2h 5-FU infusion 600mg/m5-FU infusion 600mg/m2 2 22h22h2h2h
5-FU bolus 400mg/m5-FU bolus 400mg/m22
Leucovorin 200mg/mLeucovorin 200mg/m22
cycle repeated every 14 dayscycle repeated every 14 days
FOLFOX 4 (Folinic acid, 5-FU, Oxaliplatin)
Training Module 6 – Version 1.1
For Internal Use Only
®
Oxaliplatin 100mg/mOxaliplatin 100mg/m22
Leucovorin 400mg/mLeucovorin 400mg/m22
Liver Cancer Treatment
Chemotherapy regimen in the management of unresectable metastatic colorectal cancer (mCRC):
48 hours (2 days)48 hours (2 days)
5-FU bolus 400mg/m5-FU bolus 400mg/m22
5-FU infusion 2400-3000mg/m5-FU infusion 2400-3000mg/m2 2 over 46-48hover 46-48h2h2h
cycle repeated every 14 dayscycle repeated every 14 days
FOLFOX 6 (Folinic acid, 5-FU, Oxaliplatin)
Training Module 6 – Version 1.1
For Internal Use Only
®
Oxaliplatin 85mg/mOxaliplatin 85mg/m22
Leucovorin 400mg/mLeucovorin 400mg/m22
Liver Cancer Treatment
Chemotherapy regimen in the management of unresectable metastatic colorectal cancer (mCRC):
48 hours (2 days)48 hours (2 days)
5-FU bolus 400mg/m5-FU bolus 400mg/m22
5-FU infusion 2400-3000mg/m5-FU infusion 2400-3000mg/m2 2 over 46-48hover 46-48h2h2h
cycle repeated every 14 dayscycle repeated every 14 days
FOLFOX 6m (Folinic acid, 5-FU, Oxaliplatin)
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Chemotherapy regimen in the management of unresectable metastatic colorectal cancer (mCRC):
Oxaliplatin (FOLFOX) and irinotecan (FOLFIRI) based regimen seem to have similar safety and efficacy, with differing toxicity profiles.
Irinotecan 180mg/mIrinotecan 180mg/m22
Leucovorin 200mg/mLeucovorin 200mg/m22
Oxaliplatin 100mg/mOxaliplatin 100mg/m22
Leucovorin 400mg/mLeucovorin 400mg/m22 or
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Duration of chemotherapy:
Traditional practice is to continue chemotherapy until:
Unacceptable toxicity
Clinical deterioration
Disease progression
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
New chemotherapeutic drugs (mCRC):
Capecitabine (Xeloda®)Orally administered 5-FU precursorAs effective as intravenous 5-FU/Leucovorin
Bevacizumab (Avastin®)Monoclonal antibody Target: Vascular endothelial growth factorAntiangiogenesis In combination with FOLFOX
Cetuximab (Erbitux®)Monoclonal antibodyTarget: Epidermal growth factor receptorAffecting cellular growth, differentiation and
survivalIn combination with irinotecan or alone
Training Module 6 – Version 1.1
For Internal Use Only
®
Surgical Resection
Liver Transplantation
Radiation Therapy
Radiofrequenzy Ablation
Cryosurgery
Local Chemotherapy
Percutaneous Ethanol Injection
Systemic Chemotherapy
Liver Cancer Treatment
Training Module 6 – Version 1.1
For Internal Use Only
®
Liver Cancer Treatment
Other ablative modalities:
PAI – Percutaneous Acetic Acid Injection
MCT – Microwave Coagulation Therapy
LT – Laser Therapy